Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study

Key Points

• Evinacumab notably improves cholesterol levels in patients with homozygous familial hypercholesterolaemia, indicating a strong therapeutic effect.
• The study reveals that genotypes affect the response to evinacumab, with some patients experiencing greater LDL reduction.
• Subanalysis from the ELIPSE open-label extension study provided insights into the role of low-density lipoprotein receptor function.
• These findings highlight the need for personalized treatment strategies to optimize cholesterol-lowering therapies.